| 000 | 04698cam a2200433Ii 4500 | ||
|---|---|---|---|
| 988 | _aSpringer_Medicine_2017 | ||
| 999 |
_c94740 _d94740 _x1 |
||
| 001 | 94740 | ||
| 003 | ES-MaUEC | ||
| 005 | 20230102112629.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 161019t20172017sz ob 000 0 eng d | ||
| 020 |
_a3319321102 _q(electronic bk.) |
||
| 020 |
_a9783319321103 _q(electronic bk.) |
||
| 020 | _z3319321080 | ||
| 020 | _z9783319321080 | ||
| 035 | _a(OCoLC)960909717 | ||
| 040 |
_aN$T _cN$T _dN$T _dOCLCO _dIDEBK _dGW5XE _dCOO _dYDX _dUAB _dIOG _dESU _dZ5A _dJBG _dIAD _dICW _dICN _dOTZ _dOCLCQ _dU3W _dES-MaUEC _bspa |
||
| 050 | 4 |
_aRC280.O8 _b2017 EB |
|
| 245 | 0 | 0 |
_aOvarian cancers : _badvances through international research cooperation (GINECO, ENGOT, GCIG) _cEric Pujade-Lauraine, Isabelle Ray-Coquard, Fabrice Lécuru, editors. |
| 264 | 1 |
_aSwitzerland _bSpringer _c[2017] |
|
| 264 | 4 | _c2017 | |
| 300 | _a1 recurso en línea | ||
| 336 |
_aTexto _btxt _2rdacontent |
||
| 337 |
_aelectrónico _bc _2rdamedia |
||
| 338 |
_arecurso electrónico _bcr _2rdacarrier |
||
| 500 | _aSpringerLink | ||
| 504 | _aIncluye referencias bibliográficas | ||
| 505 | 0 | _aOvarian cancer management -- Clinical research in Europe dedicated to ovarian cancers -- Oncogenetics -- Debulking surgery: Interval debulking surgery vs primary: pro and con. How to evaluate quality -- How to evaluate tumor burden before therapeutic decision -- Value of lymphadenectomy -- HYPEC: what is the evidence? -- Onco-fertility applied to ovarian cancers -- First-line systemic therapy (chemo/antiangiogenics) -- Elderly -- Treatment at relapse (surgery & systemic treatments) -- How to evaluate QoL -- The future in ovarian cancers & place of the new immunotherapies in ovarian cancers -- Particular types of ovarian cancers -- High grade serous carcinoma & BRCA mutation anti-PARP -- Borderline and low grade carcinoma -- Clear Cell carcinoma -- Endometrioid carcinoma -- Mucinous carcinoma -- Carcinosarcoma -- Germ cell tumors -- Sex cord tumors -- Very rare ovarian malignant tumors including small cell carcinoma. Ovarian cancer management -- Clinical research in Europe dedicated to ovarian cancers -- Oncogenetics -- Debulking surgery: Interval debulking surgery vs primary: pro and con. How to evaluate quality -- How to evaluate tumor burden before therapeutic decision -- Value of lymphadenectomy -- HYPEC: what is the evidence? -- Onco-fertility applied to ovarian cancers -- First-line systemic therapy (chemo/antiangiogenics) -- Elderly -- Treatment at relapse (surgery & systemic treatments) -- How to evaluate QoL -- The future in ovarian cancers & place of the new immunotherapies in ovarian cancers -- Particular types of ovarian cancers -- High grade serous carcinoma & BRCA mutation anti-PARP -- Borderline and low grade carcinoma -- Clear Cell carcinoma -- Endometrioid carcinoma -- Mucinous carcinoma -- Carcinosarcoma -- Germ cell tumors -- Sex cord tumors -- Very rare ovarian malignant tumors including small cell carcinoma. | |
| 520 | 3 | _aThis book provides an overview of the latest developments in the concepts and management of ovarian cancer. The new data presented throughout opens the way to radically different therapeutic approaches. Surgery remains the core of ovarian cancer treatment, but its ultimate goal and the standard surgical procedure have evolved, giving rise to the question of how to label expert centers for debulking surgery. Neo-adjuvant chemotherapy is becoming more popular and is also a new field for testing novel drug combinations. Over recent years, ovarian cancer management has embraced molecular biology. It is now more correct to talk about cancers of the ovary rather than ovarian cancer, since it is not a unique disease but several entities with different molecular drivers. The significant advances in drugs targeting the microenvironment or the tumor cell DNA repair mechanisms are presented in detail together with exciting future perspectives. All these advances would not have been possible without collaborative groups such as the GINECO group in France and their integration in wider clinical research networks at the European (ENGOT) and international (GCIG) level. | |
| 588 | 0 | _aVersión impresa | |
| 650 | 7 |
_2embne _aOvarios _xCáncer _9225524 |
|
| 700 | 1 |
_aLécuru, Fabrice, _eeditor literario |
|
| 700 | 1 |
_aPujade-lauraine, Eric, _eeditor literario |
|
| 700 | 1 |
_aRay-coquard, Isabelle, _eeditor literario |
|
| 856 | 4 | 0 |
_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-32110-3 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 942 |
_2lcc _cLE |
||
| 998 |
_b02/2018 _dz _e- _zSI |
||